Explore the Agenda
8:30 am Registration & Coffee
Workshop A
9:30 am Discovering the Next-Generation of TCR Targets to Expand Patient Reach & Improve Therapeutic Impact
Uncover how the field is moving beyond familiar targets like MAGE-A4 and PRAME to identify novel antigens that expand patient reach and improve clinical outcomes. This workshop dives into cutting-edge technologies, non-canonical targets, and next-generation engineering strategies that are redefining TCR therapy. Gain practical insights into building robust discovery pipelines, validating tumor specificity, and designing therapies that stand out in a competitive landscape.
Join this workshop to:
- Explore emerging target spaces including non-canonical antigens, alternative HLA molecules, and strategies to increase prevalence and density for broader patient access
- Find new ways to expedite the target validation process using a broad range of tools
- Apply computational tools to discover and validate targets faster and more accurately
- Design next-generation TCR formats to maximize efficacy and durability of response
12:30 pm Lunch Break & Networking
Workshop B
1:30 pm Leveraging Novel Engineering Strategies to Overcome Tumor Escape & Amplify Potency
As solid tumors continue to present challenges such as heterogeneity, immune evasion, and poor durability, the field is increasingly turning to advanced engineering solutions to redefine therapeutic potential. This workshop will explore cutting-edge approaches, from multi-antigen targeting strategies to next-generation TCR formats designed to amplify potency, mitigate tumor escape, and deliver deeper more durable responses that improve both patient outcomes and commercial viability.
Join this workshop to:
- Develop multi-target strategies that reduce tumor escape and expand therapeutic reach across diverse solid tumor indications
- Explore the engineering of next-generation constructs that maximize potency while maintaining safety and an optimal patient experience
- Establish best practices for monitoring cell persistence using advanced bioanalytical assays
- Assess half-life profiles to overcome dosing challenges while minimizing patient burden